… randomized, phase II study aimed to evaluate erlotinib plus fulvestrant versus erlotinib alone
… OS observed with erlotinib plus fulvestrant when considering all of the patients, a subgroup …

… randomised Phase II study assessed xentuzumab plus everolimus and exemestane in
patients … plus fulvestrant versus fulvestrant; median PFS 1.9–2.7 months) [25, 26]. In both …

… In this phase II study, we used everolimus in addition to the most recent endocrine therapy
during which a patient's … therapies in this study: exemestane (11 patients; 23%), fulvestrant (10 …

… patients with advanced NSCLC with high-dose fulvestrant in combination with erlotinib in a
phase 2 clinical trial … ) and overall survival (OS) in patients with wild-type EGFR tumors but not …

… phase II trial compared the combination of fulvestrant and erlotinib versus single-agent erlotinib
in NSCLC patients (… This work suggests that fulvestrant and dacomitinib may be effective …

… of this study, it is reasonable to use either fulvestrant or … In another randomized phase
II study (NCT01684215) of the … erlotinib in third-line therapy of KRAS-mutated metastatic …

… a phase II randomized clinical trial, the EGFR TKI erlotinib … patients who received the dual
therapy. The improvement when combining erlotinib (which only targets EGFR) with fulvestrant …

… patients with ER + HER2 mutant MBC treated with neratinib plus fulvestrant, an overall RR of
18.2% (2… HER-directed TKI, specifically lapatinib and erlotinib, is reduced in the presence of …

… by which survival is extended for patients with cancer who are treated with … clinical trial
design or biases in the interpretation of data. This study was designed to examine the role of study …

… AIs or fulvestrant (as indicated), or other anticancer agents such as PI3K or mTOR inhibitors.
To this end, two ongoing phase II studies in China are evaluating FCN-437c alone versus in …